Drugs / Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

Follow last change Jun 2025 re-read 9 days ago

Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

Developed for: lymphoid leukemia
Investigated by: American Society of Hematology · Melody Smith · National Cancer Institute (NCI) · National Marrow Donor Program

today NCT05507827 · Ph 1

2023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT05507827	Aug 2022 → Jun 2025 overdue	lymphoid leukemia	Melody Smith	Active not recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05507827 ↗
Modality	Cell therapy	“Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector” NCT05507827 ↗
Route	Intravenous	“via IV administration” NCT05507827 ↗
Target	CD19	“CD19/CD22-BBz) chimeric antigen receptor (CAR)” NCT05507827 ↗
Target	CD22	“CD19/CD22-BBz) chimeric antigen receptor (CAR)” NCT05507827 ↗